Axsome Therapeutics, Inc. (AXSM) News
Follow Axsome Therapeutics, Inc. (AXSM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank
Ratings actions from Benzinga: GMT) Axsome Therapeutics Price Target Cut to $267.00/Share From $280.00 by Deutsche BankRatings actions from Benzinga
NEWS | Sep 29, 2026, 02:35 PM UTC
H
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
The biotech sector is heading into the third-quarter earnings season with a tug-of-war between higher interest rates and an unusually heavy pipeline of company-specific catalysts. The SPDR S&P Biotech ETF (NYSE: XBI ) is
LIVE | Sep 25, 2026, 08:19 PM UTC
L
Axsome Therapeutics Price Target Cut to $247.00/Share From $251.00 by Morgan Stanley
Ratings actions from Benzinga: GMT) Axsome Therapeutics Is Maintained at Equal-Weight by Morgan StanleyRatings actions from Benzinga
NEWS | Sep 25, 2026, 04:58 PM UTC
L
Axsome Therapeutics Is Maintained at Buy by Truist Securities
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 03:58 PM UTC
L
Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target
Truist Securities maintained their Buy rating on Axsome Therapeutics's stock with a price target of $285.00.The price target implies an upside of 40.3% from the Sep 22 close of $203.10.Key takeaways from the analyst note
EQUITY | Sep 23, 2026, 03:49 PM UTC
M
Weekly recap highlights Axsome Q2 revenue jump and PDUFA timeline
Axsome Therapeutics reported Q2 revenue of $218.4M, driven by AUVELITY, with strong Medicare 65+ sales and seven ongoing trials. The recap also notes an upcoming FDA PDUFA and Phase 3 readouts; Piper Sandler reiterated o
EQUITY | Sep 21, 2026, 11:29 AM UTC
H
AXSM - Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
AXSM - Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
GEOPOLITICS | Sep 21, 2026, 11:00 AM UTC
H
AXSM - Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
AXSM - Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
GEOPOLITICS | Sep 17, 2026, 11:00 AM UTC
L
AXSM: AUVELITY's growth accelerates in new indications, with strong pipeline and financial outlook
China-originated innovation and AI are shaping R&D and commercial operations, while AUVELITY's launch shows strong growth, especially in the Medicare 65+ segment. Conservative market assumptions support an $8 billion pea
EARNINGS | Sep 14, 2026, 08:05 PM UTC
H
AXSM: AUVELITY's ADA launch accelerates growth as pipeline and financials position for profitability
China-originated innovation and AI are shaping operations, while policy focus is on IRA negotiations. AUVELITY's growth is accelerating, especially in ADA, with robust sampling and conservative $8B peak sales guidance. P
EARNINGS | Sep 14, 2026, 06:56 PM UTC
L
AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’
Shares of Axsome Therapeutics (AXSM) rose 6% on Friday after Mizuho analyst Graig Suvannavejh said August prescription data pointed to a strong start for the drug’s newest use.Citing Bloomberg Symphony figures for the 30
EQUITY | Sep 11, 2026, 07:04 PM UTC
L
AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials
Robust commercial growth is driven by AUVELITY's expanded sales force and new Alzheimer's agitation indication, with strong Medicare coverage and early positive feedback. The late-stage pipeline includes multiple phase I
EQUITY | Sep 09, 2026, 09:30 PM UTC
L
AXSM: Strong commercial momentum and late-stage pipeline position for continued growth and profitability
Robust commercial growth is driven by expanded sales efforts and new indications, especially for AUVELITY, which is seeing strong uptake in both community and long-term care settings. Financials are strong with improved
EQUITY | Sep 09, 2026, 09:09 PM UTC
L
Axsome Therapeutics to participate in September investor conferences
Axsome Therapeutics said it will participate in upcoming investor conferences in September. The company did not provide additional details in the release excerpt.
EQUITY | Sep 02, 2026, 11:08 AM UTC
L
AXSM - Axsome Therapeutics to Participate in Upcoming Investor Conferences
AXSM - Axsome Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
HC Wainwright & Co. maintains $290 price target on Axsome
HC Wainwright & Co. maintained a $290.00/share price target for Axsome Therapeutics.
EQUITY | Aug 31, 2026, 03:42 PM UTC
L
AXSM Initiate with an Outperform, $310 PT @ BMO
AXSM Initiate with an Outperform, $310 PT @ BMO
EQUITY | Jul 21, 2026, 12:05 PM UTC
L
Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application
() -- Axsome Therapeutics (AXSM) said Wednesday the US Food and Drug Administration accepted its new drug application for AXS-12 to treat cataplexy, or muscle weakness, in narcolepsy. A target review date of May 1, 2027,
REGULATION | Jul 15, 2026, 11:52 AM UTC
L
AXSM Axsome Therapeutics announces FDA Acceptance of new drug application for axs-12 for the treatment of cataplexy in narcolepsy Axsome The
AXSM Axsome Therapeutics announces FDA Acceptance of new drug application for axs-12 for the treatment of cataplexy in narcolepsy Axsome Therapeutics - FDA sets pdufa target action date of may 1, 2027 for axs-12 NDA - FD
REGULATION | Jul 15, 2026, 11:01 AM UTC
M
AXSM Initiates ADHD Trial
Axsome Therapeutics initiates FOCUS-3 Phase 3 trial of Solriamfetol in adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
EQUITY | Jun 26, 2026, 11:00 AM UTC